Dr. Mark Souweidane, a dedicated and active member of the Pediatric Brain Tumor Consortium, is hosting a symposium on Novel Drug Delivery Systems in CNS Tumors. The meeting will take place in advance of the broader annual PBTC meeting symposium on Sunday, October 6, 2019, 3 – 7PM MST at the Grand Hyatt Hotel in Denver.
The symposium will focus on the translational aspects of these novel systems, and the overall goal is to discuss potential future clinical trials using new delivery systems, including a possible trial concept, contemporary pre-clinical and clinical experiences, and barriers to development.
Topics will include direct drug delivery, intrathecal drug delivery, intra-arterial drug delivery, magnetic resonance guided focused ultrasound, and laser interstitial thermal therapy. Participants will include clinical trialists, neuro-oncologists, neurosurgeons, radiation oncologists, basic and translational scientists and those with experience in clinical trial regulatory aspects necessary for moving these novel concepts forward.
“This meeting is essential if we want to collaborate on various drug delivery approaches and make them available to children via clinical trial on a global scale,” said Dr. Mark Souweidane. “We will be discussing next steps in clinical trial design, and some of the roadblocks we are facing in moving these collaborative efforts forward, including funding.”
Founded by the NCI in 1999 and consisting of 12 participating academic centers and children’s hospitals across the country, the PBTC is a multi-disciplinary cooperative research organization devoted to the study of correlative tumor biology and new therapies for primary CNS tumors of childhood.
To help fund these efforts, you can donate here.